Switching Antidepressants After a First Selective Serotonin Reuptake Inhibitor in Major Depressive Disorder: A Systematic Review
The DOI matches its Crossref record; 134 of the 134 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: Selective serotonin reuptake inhibitors (SSRIs) are frequently used as a first antidepressant for major depressive disorder but have response rates of 50% to 60% in daily practice. For patients with insufficient response to SSRIs, switching is often applied. This article aims to systematically review the evidence for switching pharmacotherapy after a first SSRI. DATA SOURCES: A systematic literature search (updated until Feb. 10, 2005) in MEDLINE, EMBASE, CINAHL, and PsychINFO (all indexed years) identified randomized, controlled trials (RCTs) and open studies investigating switching strategies. In the absence of specific keywords for switching, we performed "sensitive" searches using free text words with wildcards ($): "switch$" or ("alternat$" adj5 "treat$") or ("alternat$" adj5 "therap$") in combination with the Cochrane Collaboration search filter for RCTs, the Cochrane Collaboration Depression Anxiety and Neurosis Group search filter for major depressive disorder, and MeSH terms for antidepressants (in combination with additional text words for all antidepressive agents). Additionally, we included 4 recent Sequenced Treatment Alternatives to Relieve Depression publications. We limited searches to adults and humans but did not apply language restrictions. STUDY SELECTION: Relevant articles were retrieved and critically appraised. The methodology of the studies, the results on efficacy and dropouts due to side effects, and remarks were summarized in an evidence table. Three studies comparing a switch to venlafaxine or SSRIs were pooled. DATA SYNTHESIS: Eight RCTs and 23 open studies were identified, studying populations with different levels of treatment resistance. Definitions of response and remission rates varied between studies. Observed response rates after switching to any of the classes of antidepressants varied between 12% and 86%. Remission rates varied between 7% and 82%. The number of previous treatments with antidepressants was negatively correlated with treatment outcome. Rates of dropout due to side effects varied considerably across agents (5%-39%). Switching to venlafaxine showed a modest and clinically equivocal benefit over SSRIs (number needed to treat = 13 [95% CI = 9.1 to 25.0]). CONCLUSIONS: After a first SSRI, any switch within or between classes of antidepressants appears legitimate (second SSRI, novel dual-acting antidepressants, selective norepinephrine or nor-adrenergic/dopaminergic agents, or tricyclic anti-depressant or mianserin). No unequivocal evidence is available to prove an advantage of a between-class switch. More guidance by randomized empirical studies is needed. Clinical implications and methodological considerations for future studies are discussed.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Citations
Cites
Hamilton, M. (1960) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.23.1.56 · Cited by 32,817
A new depression scale designed to be sensitive to change
Montgomery, S. A., & Åsberg, M. (1979) · British Journal of Psychiatry · doi:10.1192/bjp.134.4.382 · Cited by 13,962
(1976) · Medical Entomology and Zoology · Cited by 8,899
Evidence-Based Medicine: How to Practice and Teach EBM
Sackett, D. L. (2000) · Cited by 5,950
Rush, A. J., Trivedi, M. H., Ibrahim, H. M., Carmody, T. J., Arnow, B., Klein, D. N., Markowitz, J. C., Ninan, P. T., Kornstein, S., Manber, R., et al. (2003) · Biological Psychiatry · doi:10.1016/s0006-3223(02)01866-8 · Cited by 3,829 · cited 1×
“the 16-item quick inventory for depressive symptomsself-rated (QIDS-SR16).(57) For tolerability, we took the dropout rate due to side effects as primary measure, followed by the overall dropout rate.”
MethodEvidence-based health policy—lessons from the Global Burden of Disease Study
Murray, C. J. L., & Lopez, A. D. (1996) · Science · doi:10.1126/science.274.5288.740 · Cited by 2,178
New approaches to antidepressant drug discovery: beyond monoamines
Berton, O., & Nestler, E. J. (2006) · Nature Reviews Neuroscience · doi:10.1038/nrn1846 · Cited by 1,589
Keller, M. B., McCullough, J. P., Klein, D. N., Arnow, B., Dunner, D. L., Gelenberg, A. J., Markowitz, J. C., Nemeroff, C. B., Russell, J. M., Thase, M. E., et al. (2000) · New England Journal of Medicine · doi:10.1056/nejm200005183422001 · Cited by 1,331
Sequenced treatment alternatives to relieve depression (STAR*D): Rationale and design
Rush, A. J., Fava, M., Wisniewski, S. R., Lavori, P. W., Trivedi, M. H., Sackeim, H. A., Thase, M. E., Nierenberg, A. A., Quitkin, F. M., Kashner, T. M., et al. (2004) · Controlled Clinical Trials · doi:10.1016/s0197-2456(03)00112-0 · Cited by 1,076
Bupropion-SR, Sertraline, or Venlafaxine-XR after Failure of SSRIs for Depression
Rush, A. J., Trivedi, M. H., Wisniewski, S. R., Stewart, J. W., Nierenberg, A. A., Thase, M. E., Ritz, L., Biggs, M. M., Warden, D., Luther, J. F., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa052963 · Cited by 1,033
Medication Augmentation after the Failure of SSRIs for Depression
Trivedi, M. H., Fava, M., Wisniewski, S. R., Thase, M. E., Quitkin, F., Warden, D., Ritz, L., Nierenberg, A. A., Lebowitz, B. D., Biggs, M. M., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa052964 · Cited by 1,002
Anderson, I., Ferrier, I., Baldwin, R., Cowen, P., Howard, L., Lewis, G., Matthews, K., McAllister-Williams, R., Peveler, R., Scott, J., et al. (2008) · Journal of Psychopharmacology · doi:10.1177/0269881107088441 · Cited by 908
Keller, M. B. (1992) · Archives of General Psychiatry · doi:10.1001/archpsyc.1992.01820100053010 · Cited by 864
(1997) · PubMed · Cited by 727
Bero, L. (1995) · JAMA · doi:10.1001/jama.1995.03530240045039 · Cited by 714
Fava, M., & Kendler, K. S. (2000) · Neuron · doi:10.1016/s0896-6273(00)00112-4 · Cited by 603
Selective serotonin reuptake inhibitor discontinuation syndrome: a randomized clinical trial
Rosenbaum, J. F., Fava, M., Hoog, S. L., Ascroft, R. C., & Krebs, W. B. (1998) · Biological Psychiatry · doi:10.1016/s0006-3223(98)00126-7 · Cited by 574
Treatment-Resistant Depression
(2015) · Encyclopedia of Psychopharmacology · doi:10.1007/978-3-642-36172-2_200431 · Cited by 488
The Medical Management of Depression
Mann, J. J. (2005) · New England Journal of Medicine · doi:10.1056/nejmra050730 · Cited by 421
George, M. S., Rush, A. J., Marangell, L. B., Sackeim, H. A., Brannan, S. K., Davis, S. M., Howland, R., Kling, M. A., Moreno, F., Rittberg, B., et al. (2005) · Biological Psychiatry · doi:10.1016/j.biopsych.2005.07.028 · Cited by 372
Fava, M., Rush, A. J., Wisniewski, S. R., Nierenberg, A. A., Alpert, J. E., McGrath, P. J., Thase, M. E., Warden, D., Biggs, M., Luther, J. F., et al. (2006) · American Journal of Psychiatry · doi:10.1176/ajp.2006.163.7.1161 · Cited by 362
Meta-analytical studies on new antidepressants
Anderson, I. M. (2001) · British Medical Bulletin · doi:10.1093/bmb/57.1.161 · Cited by 351
McGrath, P. J., Stewart, J. W., Fava, M., Trivedi, M. H., Wisniewski, S. R., Nierenberg, A. A., Thase, M. E., Davis, L., Biggs, M. M., Shores-Wilson, K., et al. (2006) · American Journal of Psychiatry · doi:10.1176/ajp.2006.163.9.1531 · Cited by 350
Trivedi, M. H., Rush, A. J., Crismon, M. L., Kashner, T. M., Toprac, M. G., Carmody, T. J., Key, T., Biggs, M. M., Shores-Wilson, K., Witte, B., et al. (2004) · Archives of General Psychiatry · doi:10.1001/archpsyc.61.7.669 · Cited by 316
Similar Effectiveness of Paroxetine, Fluoxetine, and Sertraline in Primary Care: A Randomized Trial
Kroenke, K., West, S. L., Swindle, R., Gilsenan, A., Eckert, G. J., Dolor, R., Stang, P., Zhou, X.-H., Hays, R., & Weinberger, M. (2001) · JAMA · doi:10.1001/jama.286.23.2947 · Cited by 312
Lithium Augmentation in Treatment-Resistant Depression: Meta-Analysis of Placebo-Controlled Studies
Bauer, M., & Döpfmer, S. (1999) · Journal of Clinical Psychopharmacology · doi:10.1097/00004714-199910000-00006 · Cited by 304
(2001) · PubMed · Cited by 303
Anderson, I. M. (1998) · Depression and Anxiety · doi:10.1002/(sici)1520-6394(1998)7:1+<1::aid-da1>3.3.co;2-j · Cited by 278
Bollini, P., Pampaliona, S., Tibaldi, G., Kupelnick, B., & Munizza, C. (1999) · British Journal of Psychiatry · doi:10.1192/bjp.174.4.297 · Cited by 274
Anderson, I. M. (1998) · Depression and Anxiety · doi:10.1002/(sici)1520-6394(1998)7:1+<11::aid-da4>3.0.co;2-i · Cited by 266
Gilbert, D. A., Altshuler, K. Z., Rago, W. V., Shon, S. P., Crismon, M. L., Toprac, M. G., & Rush, A. J. (1998) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v59n0702 · Cited by 264
Interpretation of Kappa and B statistics measures of agreement
Munoz, S. R., & Bangdiwala, S. I. (1997) · Journal of Applied Statistics · doi:10.1080/02664769723918 · Cited by 244
Evidence-Based Medicine : How to Practice and Teach
Sackett, D. L. (2000) · Medical Entomology and Zoology · Cited by 240
RECOVERY, CHRONICITY, AND LEVELS OF PSYCHOPATHOLOGY IN MAJOR DEPRESSION
Mueller, T. I., & Leon, A. C. (1996) · Psychiatric Clinics of North America · doi:10.1016/s0193-953x(05)70275-6 · Cited by 234
Thase, M. E., Blomgren, S. L., Birkett, M. A., Apter, J. T., & Tepner, R. G. (1997) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v58n0103 · Cited by 204
Venlafaxine for Treatment-Resistant Unipolar Depression
NIERENBERG, A. A., FEIGHNER, J. P., RUDOLPH, R., COLE, J. O., & SULLIVAN, J. (1994) · Journal of Clinical Psychopharmacology · doi:10.1097/00004714-199412000-00008 · Cited by 198
Partial Response and Nonresponse to Antidepressant Therapy: Current Approaches and Treatment Options
Hirschfeld, R. M. A., Montgomery, S. A., Aguglia, E., Amore, M., Delgado, P. L., Gastpar, M., Hawley, C., Kasper, S., Linden, M., Massana, J., et al. (2002) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v63n0913 · Cited by 193
Kennedy, S. H., Lam, R. W. M., Cohen, N. L., & Ravindran, A. V. (2001) · PubMed · Cited by 191
Development of a quality assessment instrument for trials of treatments for depression and neurosis
Moncrieff, J., Churchill, R., Drummond, D. C., & McGuire, H. (2001) · International Journal of Methods in Psychiatric Research · doi:10.1002/mpr.108 · Cited by 185
Venlafaxine and paroxetine in treatment-resistant depression
Gregson, J. (1999) · British Journal of Psychiatry · doi:10.1192/bjp.175.6.591a · Cited by 171
Stimpson, N., Agrawal, N., & Lewis, G. (2002) · British Journal of Psychiatry · doi:10.1192/bjp.181.4.284 · Cited by 157
Strengthening clinical effectiveness trials: Equipoise-stratified randomization
Lavori, P. W., Rush, A. J., Wisniewski, S. R., Alpert, J. E., D, M. F. M., Kupfer, D. J., Nierenberg, A. A., Quitkin, F. M., Sackeïm, H. A., Thase, M. E., et al. (2001) · Biological Psychiatry · doi:10.1016/s0006-3223(01)01223-9 · Cited by 153
Beyond the monoamine hypothesis: mechanisms, molecules and methods
Hindmarch, I. (2002) · European Psychiatry · doi:10.1016/s0924-9338(02)00653-3 · Cited by 151
Fava, M., & Rush, A. J. (2006) · Psychotherapy and Psychosomatics · doi:10.1159/000091771 · Cited by 151
Thase, M. E., Rush, A. J., Howland, R. H., Kornstein, S. G., Kocsis, J. H., Gelenberg, A. J., Schatzberg, A. F., Koran, L. M., Keller, M. B., Russell, J. M., et al. (2002) · Archives of General Psychiatry · doi:10.1001/archpsyc.59.3.233 · Cited by 144
Owens, M. J. (2004) · PubMed · Cited by 137
Improvement in fluoxetine-associated sexual dysfunction in patients switched to bupropion.
Walker, P. W., Cole, J. O., Gardner, E. A., Hughes, A. R., Johnston, J. A., Batey, S. R., & Lineberry, C. G. (1993) · PubMed · Cited by 132
Fredman, S. J., Fava, M., Kienke, A. S., White, C. N., Nierenberg, A. A., & Rosenbaum, J. F. (2000) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v61n0602 · Cited by 132
Thase, M. E., Frank, E., Mallinger, A. G., Hamer, T., & Kupfer, D. J. (1992) · PubMed · Cited by 114
New approaches to the treatment of refractory depression.
Fava, M. (2000) · PubMed · Cited by 114
Combining Antidepressants for Treatment-Resistant Depression: A Review
Lam, R. W., Wan, D. D. C., Cohen, N. L., & Kennedy, S. H. (2002) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v63n0805 · Cited by 113
Ferreri, M., Lavergne, F., Berlin, I., Payan, C., & Puech, A. J. (2001) · Acta Psychiatrica Scandinavica · doi:10.1034/j.1600-0447.2001.00148.x · Cited by 108
How antidepressants help depression: mechanisms of action and clinical response.
Delgado, P. L. (2004) · PubMed · Cited by 107
Nortriptyline for Treatment-Resistant Depression
Nierenberg, A. A., Papakostas, G. I., Petersen, T., Kelly, K. E., Iacoviello, B. M., Worthington, J. J., Tedlow, J., Alpert, J. E., & Fava, M. (2003) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v64n0108 · Cited by 106
Smeraldi, E. (1998) · Journal of Affective Disorders · doi:10.1016/s0165-0327(97)00139-0 · Cited by 104
Management of nonresponse and intolerance: switching strategies.
D, M. F. M. (2000) · PubMed · Cited by 103
Lithium Augmentation of Nortriptyline for Subjects Resistant to Multiple Antidepressants
Nierenberg, A. A., Papakostas, G. I., Petersen, T., Montoya, H. D., Worthington, J. J., Tedlow, J., Alpert, J. E., & Fava, M. (2003) · Journal of Clinical Psychopharmacology · doi:10.1097/00004714-200302000-00013 · Cited by 103
Lithium augmentation therapy in refractory depression?Update 2002
Bauer, M., Forsthoff, A., Baethge, C., Adli, M., Berghöfer, A., D�pfmer, S., & Bschor, T. (2003) · European Archives of Psychiatry and Clinical Neuroscience · doi:10.1007/s00406-003-0430-9 · Cited by 101
(1993) · American Journal of Psychiatry · doi:10.1176/ajp.150.1.118 · Cited by 101
Are patients who are intolerant to one serotonin selective reuptake inhibitor intolerant to another?
Brown, W. A., & Harrison, W. M. (1995) · PubMed · Cited by 95
Fava, M., Dunner, D. L., Greist, J. H., Preskorn, S. H., Trivedi, M. H., Zajecka, J., & Cohen, M. (2001) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v62n0603 · Cited by 94
Nolen, W. A., Putte, J. J. V. D., Dijken, W. A., Kamp, J. S., Blansjaar, B. A., Kramer, H. J., & Haffmans, J. (1988) · Acta Psychiatrica Scandinavica · doi:10.1111/j.1600-0447.1988.tb06403.x · Cited by 91
Lam, R. W., Hossie, H., Solomons, K., & Yatham, L. N. (2004) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v65n0308 · Cited by 88
Discontinuation symptoms: comparison of brief interruption in fluoxetine and paroxetine treatment
Judge, R., Parry, M. G., Quail, D., & Jacobson, J. G. (2002) · International Clinical Psychopharmacology · doi:10.1097/00004850-200209000-00002 · Cited by 87
Venlafaxine in Treatment-Resistant Major Depression: A Canadian Multicenter, Open-Label Trial
de Montigny, C., Silverstone, P. H., Debonnel, G., Blier, P., & Bakish, D. (1999) · Journal of Clinical Psychopharmacology · doi:10.1097/00004714-199910000-00003 · Cited by 85
Response to an open trial of a second SSRI in major depression.
Joffe, R. T., LEVITT, A. J., Sokolov, S. T. H., & Young, L. T. (1996) · PubMed · Cited by 84
Characteristics of responders to fluoxetine.
Reimherr, F. W., Wood, D. R., Byerley, B., Brainard, J., & Bi, G. (1984) · PubMed · Cited by 82
Mischoulon, D., Nierenberg, A. A., Kizilbash, L., Rosenbaum, J. F., & Fava, M. (2000) · The Canadian Journal of Psychiatry · doi:10.1177/070674370004500509 · Cited by 81
Consensus guidelines in the treatment of major depressive disorder.
Rush, A. J., Crismon, M. L., Toprac, M. G., Trivedi, M. H., Rago, W. V., Shon, S., & Altshuler, K. Z. (1998) · PubMed · Cited by 79
Serum trace elements in animal models and human depression. Part I. Zinc
Nowak, G., ba, A. Z., Dudek, D., Krośniak, M., Szymaczek, M., & Schlegel-Zawadzka, M. (1999) · Human Psychopharmacology Clinical and Experimental · doi:10.1002/(sici)1099-1077(199903)14:2<119::aid-hup77>3.0.co;2-1 · Cited by 78
Nolen, W. A., Putte, J. J. V. D., Dijken, W. A., Kamp, J. S., Blansjaar, B. A., Kramer, H. J., & Haffmans, J. (1988) · Acta Psychiatrica Scandinavica · doi:10.1111/j.1600-0447.1988.tb06402.x · Cited by 74
Baldomero, E. B., Ubago, J. G., Cercós, C. L., Ruiloba, J. V., Calvo, C. G., López, R. P., & for the ARGOS Study Group (2005) · Depression and Anxiety · doi:10.1002/da.20080 · Cited by 74
Charney, D. S. (1986) · Archives of General Psychiatry · doi:10.1001/archpsyc.1986.01800120041009 · Cited by 73
Thase, M. E. (2004) · CNS Spectrums · doi:10.1017/s1092852900002236 · Cited by 67
Ruhé, H. G., Huyser, J., Swinkels, J. A., & Schene, A. H. (2006) · British Journal of Psychiatry · doi:10.1192/bjp.bp.105.018325 · Cited by 67
Self-citationManaging treatment-resistant major depression.
Nelson, J. C. (2003) · PubMed · Cited by 66
Does intolerance or lack of response with fluoxetine predict the same will happen with sertraline?
Zarate, C. A., Kando, J. C., Tohen, M. F., Weiss, M. K., & Cole, J. O. (1996) · PubMed · Cited by 63
Efficacy of fluvoxamine in treatment-refractory depression
Delgado, P. L., Price, L. H., Charney, D. S., & Heninger, G. R. (1988) · Journal of Affective Disorders · doi:10.1016/0165-0327(88)90009-2 · Cited by 63
Fluoxetine efficacy in treatment resistant depression
Amsterdam, J. D., Maislin, G., & Potter, L. S. (1994) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/0278-5846(94)90057-4 · Cited by 62
Treatment of antidepressant nonresponders: augmentation or switch?
Nelson, J. C. (1998) · PubMed · Cited by 60
Treatment of tricyclic refractory depression with a monoamine oxidase inhibitor antidepressant.
McGrath, P. J., Stewart, J. W., Harrison, W. M., & Quitkin, F. M. (1987) · PubMed · Cited by 58
Evidence Report: Treatment of Depression - Newer Pharmacotherapies
(1999) · Pharmacopsychiatry · doi:10.1055/s-2007-991098 · Cited by 57
Pharmacotherapy to sustain the fully remitted state
Kennedy, S., McIntyre, R., Fallu, A., & Lam, R. (2002) · Journal of Psychiatry and Neuroscience · doi:10.1139/jpn.0245 · Cited by 56
Monoamine oxidase inhibitors in resistant major depression
Nolen, W. A., Haffmans, P. M. J., Bouvy, P. F., & Duivenvoorden, H. J. (1993) · Journal of Affective Disorders · doi:10.1016/0165-0327(93)90104-r · Cited by 56
Bruijn, J. A., van den Broek, W. W., van Hulst, A. M., van den Broek, W. W., van de Wetering, B. J. M., Moleman, P., & Mulder, P. G. H. (1996) · Psychopharmacology · doi:10.1007/s002130050081 · Cited by 56
Algorithm for the treatment of chronic depression.
Trivedi, M. H., & Kleiber, B. (2001) · PubMed · Cited by 55
Switching antidepressants for treatment-resistant major depression.
Marangell, L. B. (2001) · PubMed · Cited by 51
Mitchell, P. B., Schweitzer, I., Burrows, G., Johnson, G., & Polonowita, A. (2000) · Journal of Clinical Psychopharmacology · doi:10.1097/00004714-200008000-00014 · Cited by 49
Combined antidepressants: clinical experience
Rojo, E., Ros, S., Agüera, L., de la Gándara, J., & de Pedro, J. M. (2005) · Acta Psychiatrica Scandinavica · doi:10.1111/j.1600-0447.2005.00677.x · Cited by 48
Citalopram Treatment of Fluoxetine Nonresponders
Thase, M. E., Feighner, J. P., & Lydiard, R. B. (2001) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v62n0904 · Cited by 47
Fluoxetine in tricyclic refractory major depressive disorder
Beasley, C. M., Sayler, M. E., Cunningham, G. E., Weiss, A. M., & Masica, D. N. (1990) · Journal of Affective Disorders · doi:10.1016/0165-0327(90)90144-w · Cited by 47
Baker, C. B., Tweedie, R., Duval, S., & Woods, S. W. (2003) · Depression and Anxiety · doi:10.1002/da.10079 · Cited by 42
Efficacy of venlafaxine in major depression resistant to selective serotonin reuptake inhibitors
Sáiz-Ruiz, J., Ibáñez, Á., Díaz‐Marsá, M., Árias, F., Padín, J. J., Martín-Carrasco, M., Montes, J. M. G., Ferrando, L., Carrasco, J. L., Martín-Ballesteros, E., et al. (2002) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/s0278-5846(02)00247-6 · Cited by 42
Efficacy of bupropion in tricyclic-resistant or intolerant patients.
Stern, W. C., Harto-Truax, N., & Bauer, N. (1983) · PubMed · Cited by 41
Birkenhäger, T. K., van den Broek, W. W., Mulder, P. G., Bruijn, J. A., & Moleman, P. (2004) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v65n1110 · Cited by 41
Switching Versus Augmentation: A Prospective, Naturalistic Comparison Treatment-Resistant Patients
Posternak, M. A., & Zimmerman, M. (2001) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v62n0212 · Cited by 40
Switching to Bupropion in Fluoxetine-Resistant Major Depressive Disorder
Fava, M., Papakostas, G., Petersen, T., Mahal, Y., Quitkin, F., Stewart, J., & McGrath, P. (2003) · Annals of Clinical Psychiatry · doi:10.1023/a:1023224525400 · Cited by 40
Does increasing dose improve efficacyin patients with poor antidepressantresponse: a review
Corruble, E., & Guelfi, J. D. (2000) · Acta Psychiatrica Scandinavica · doi:10.1034/j.1600-0447.2000.101005343.x · Cited by 38
A double-blind randomized study comparing imipramine with fluvoxamine in depressed inpatients
van den Broek, W. W., Birkenhäger, T. K., Mulder, P. G. H., Bruijn, J. A., & Moleman, P. (2004) · Psychopharmacology · doi:10.1007/s00213-004-1853-3 · Cited by 38
Nolen, W. A., van de Putte, J. J., Dijken, W. A., & Kamp, J. J. H. (1985) · British Journal of Psychiatry · doi:10.1192/bjp.147.1.16 · Cited by 37
Peselow, E. D., Am, F., Goodnick, P. J., Barouche, F., & Rr, F. (1989) · PubMed · Cited by 36
The dual-action hypothesis: does pharmacology matter?
Shelton, R. C. (2004) · PubMed · Cited by 35
Fava, M., McGrath, P. J., & Sheu, W.-P. (2003) · Journal of Clinical Psychopharmacology · doi:10.1097/01.jcp.0000085409.08426.4c · Cited by 35
The use of antidepressants in novel combination therapies.
Shelton, R. C. (2003) · PubMed · Cited by 35
Kaplan, E. M. (2002) · Clinical Therapeutics · doi:10.1016/s0149-2918(02)80029-7 · Cited by 34
Medication Options in the Treatment of Treatment-Resistant Depression
PRIDMORE, S. A., & Turnier‐Shea, Y. (2004) · Australian & New Zealand Journal of Psychiatry · doi:10.1080/j.1440-1614.2004.01335.x · Cited by 30
Drug treatment of depression: reflections on the evidence
Anderson, I. M. (2002) · Advances in Psychiatric Treatment · doi:10.1192/apt.9.1.11 · Cited by 30
Pharmacological choices after one antidepressant fails: a survey of UK psychiatrists
Shergill, S. S., & Katona, C. (1997) · Journal of Affective Disorders · doi:10.1016/s0165-0327(96)00100-0 · Cited by 28
Psychiatrists' responses to failure of maintenance therapy with antidepressants
(1997) · Psychiatric Services · doi:10.1176/ps.48.6.835 · Cited by 27
Emrich, H. M., Berger, T., Riemann, D. W., & Zerssen, D. V. (1987) · Pharmacopsychiatry · doi:10.1055/s-2007-1017076 · Cited by 27
Gagiano, C. A., Muller, P. G. M., Fourie, J., & Roux, J. F. L. (1989) · Acta Psychiatrica Scandinavica · doi:10.1111/j.1600-0447.1989.tb07191.x · Cited by 27
Trazodone in Treatment-Resistant Depression: An Open Study
Cole, J. O., Schatzberg, A. F., Sniffin, C., ZOLNER, J., & Cole, J. O. (1981) · Journal of Clinical Psychopharmacology · doi:10.1097/00004714-198111001-00010 · Cited by 27
What to do if an initial antidepressant fails?
McIntyre, R. S., Müller, A., Mancini, D. A., & Silver, E. S. (2003) · PubMed · Cited by 27
Treatment-resistant depression in the age of serotonin: evolving strategies
OʼReardon, J. P., Brunswick, D. J., & Amsterdam, J. D. (2000) · Current Opinion in Psychiatry · doi:10.1097/00001504-200001000-00016 · Cited by 26
Bupropion in Tricyclic Antidepressant Nonresponders with Unipolar Major Depressive Disorder
Ferguson, J. M., Cunningham, L. A., Merideth, C., APTER, J. T., Feighner, J. P., Ionescu-Pioggia, M., Samara, B., Johnston, J. A., & Ascher, J. (1994) · Annals of Clinical Psychiatry · doi:10.3109/10401239409148997 · Cited by 25
Fluoxetine in tricyclic refractory depression in adolescents
Ghaziuddin, N., Naylor, M. W., & King, C. A. (1994) · Depression · doi:10.1002/depr.3050020602 · Cited by 23
Mirtazapine for treatment-resistant depression: a preliminary report
Wan, D. D. C., Kundhur, D., Solomons, K., Yatham, L. N., & Lam, R. W. M. (2003) · Journal of Psychiatry and Neuroscience · doi:10.1139/jpn.0306 · Cited by 22
Selective versus multi-transmitter antidepressants: are two mechanisms better than one?
Burke, W. J. (2004) · PubMed · Cited by 21
Symptoms and Circuits, Part 1: Major Depressive Disorder: (Brainstorms)
Stahl, S. M. (2003) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v64n1101 · Cited by 21
Mirtazapine versus sertraline after SSRI non-response
Thase, M. E., Kremer, C. M. E., & Rodrigues, H. (2001) · European Neuropsychopharmacology · doi:10.1016/s0924-977x(01)80503-4 · Cited by 20
Leonard, B. E. (1999) · Human Psychopharmacology Clinical and Experimental · doi:10.1002/(sici)1099-1077(199903)14:2<75::aid-hup68>3.0.co;2-x · Cited by 19
Current perspectives in the management of treatment-resistant depression
Parikh, R. M., & Lebowitz, B. D. (2004) · Dialogues in Clinical Neuroscience · doi:10.31887/dcns.2004.6.1/rparikh · Cited by 18
Kreider, M. S., Bushnell, W. D., Oakes, R., & Wheadon, D. E. (1995) · PubMed · Cited by 17
Citalopram treatment of paroxetine-intolerant depressed patients
Thase, M. E., Ferguson, J. M., Lydiard, R. B., & Wilcox, C. S. (2002) · Depression and Anxiety · doi:10.1002/da.10055 · Cited by 17
Fluvoxamine in the treatment of tricyclic-resistant depression.
White, K., Wykoff, W., Tynes, L. L., Schneider, L. S., & Zemansky, M. F. (1990) · PubMed · Cited by 16
Nortriptyline in Geriatric Depression Resistant to Serotonin Reuptake Inhibitors: Case Series
Weintraub, D. A. (2001) · Journal of Geriatric Psychiatry and Neurology · doi:10.1177/089198870101400107 · Cited by 12
Citalopram Treatment of Fluoxetine-Intolerant Depressed Patients
Calabrese, J. R., Londborg, P. D., Shelton, M. D., & Thase, M. E. (2003) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v64n0511 · Cited by 12
Sajatovic, M., DiGiovanni, S. K., Fuller, M. A., Belton, J., DeVega, E., Marqua, S., & Liebling, D. S. (1999) · Clinical Therapeutics · doi:10.1016/s0149-2918(00)88324-1 · Cited by 10
Reynaert-Dupuis, C., Zdanowicz, N., Leyman, S., Mignon, A., & Seghers, S. (2002) · Primary Care and Community Psychiatry · doi:10.1185/135525702125000967 · Cited by 8
[The concept of resistant depression and therapeutic strategies, particularly, with venlafaxine].
Poirier, M. F. (1999) · PubMed · Cited by 6
Switching Strategies for the Treatment of Unipolar Major Depression
Howland, R. H., & Thase, M. E. (1997) · KARGER eBooks · doi:10.1159/000061660 · Cited by 6
Schmauß, M., Laakmann, G., & Dieterle, D. (1985) · Pharmacopsychiatry · doi:10.1055/s-2007-1017323 · Cited by 5
Pharmacological management of treatment resistant depression: a clinical review
Kennedy, N., & McDonough, M. (2003) · Irish Journal of Psychological Medicine · doi:10.1017/s0790966700007473 · Cited by 5
Mischoulon, D., OPITZ, G. M., Kelly, K. E., Fava, M., & Rosenbaum, J. F. (2004) · Depression and Anxiety · doi:10.1002/da.10127 · Cited by 4
Cited by
Malhi, G. S., & Mann, J. J. (2018) · The Lancet · doi:10.1016/s0140-6736(18)31948-2 · Cited by 4,099
Anderson, I., Ferrier, I., Baldwin, R., Cowen, P., Howard, L., Lewis, G., Matthews, K., McAllister-Williams, R., Peveler, R., Scott, J., et al. (2008) · Journal of Psychopharmacology · doi:10.1177/0269881107088441 · Cited by 908
Malhi, G. S., Bassett, D., Boyce, P., Bryant, R., Fitzgerald, P. B., Fritz, K., Hopwood, M., Lyndon, B., Mulder, R., Murray, G., et al. (2015) · Australian & New Zealand Journal of Psychiatry · doi:10.1177/0004867415617657 · Cited by 842
“Before altering any treatment it is important to allow a trial of appropriate duration, usually three weeks, at adequate dosage (Licht and Qvitzau, 2002; Ruhé et al., 2006a).”
BackgroundInfluentialCleare, A., Pariante, C., Young, A., Anderson, I., Christmas, D., Cowen, P., Dickens, C., Ferrier, I., Geddes, J., Gilbody, S., et al. (2015) · Journal of Psychopharmacology · doi:10.1177/0269881115581093 · Cited by 759
“Reintroduction of the same class of antidepressant appears to suppress symptoms rapidly (Ruhe et al., 2006), and with SSRIs (or SNRIs) an option is to switch to fluoxetine which can then be stopped abruptly due to its long half-life.”
BackgroundMethodResultInfluentialKennedy, S. H., Lam, R. W., Parikh, S. V., Patten, S. B., & Ravindran, A. V. (2009) · Journal of Affective Disorders · doi:10.1016/j.jad.2009.06.043 · Cited by 525
Metadata
- Authors
- Ruhé, H. G., Huyser, J., Swinkels, J. A., & Schene, A. H.
- Affiliations
- Amsterdam UMC Location University of Amsterdam (NL)
- Amsterdam Neuroscience (NL)
- Venue
- The Journal of Clinical Psychiatry
- Publisher
- Physicians Postgraduate Press, Inc
- Published
- 2006-12-15
- Volume
- 67
- Issue
- 12
- Pages
- 1836-1855
- ISSN
- 0160-6689 (ISSN-L)
- OpenAlex
- W2103423058
- Cited by
- 230
- References
- 132
- Citations by year
- 2026: 1 · 2025: 7 · 2024: 4 · 2023: 9 · 2022: 6 · 2021: 10 · 2020: 7 · 2019: 12 · 2018: 12 · 2017: 16 · 2016: 9 · 2015: 16 · 2014: 17 · 2013: 14 · 2012: 13
- FWCI
- 7.73
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- The Journal of Clinical Psychiatry (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Social Sciences › Psychology › Experimental and Cognitive Psychology › Anxiety, Depression, Psychometrics, Treatment, Cognitive Processes
- Health Sciences › Medicine › Psychiatry and Mental health › Mental Health Treatment and Access
- Keywords
- antidepressant switching, major depressive disorder, selective serotonin reuptake inhibitors, treatment-resistant depression, venlafaxine, second-generation antidepressants, norepinephrine reuptake inhibitors, antidepressant efficacy comparison, number needed to treat
- MeSH terms
- Antidepressive Agents, Clinical Trials as Topic, Major Depressive Disorder, Drug Resistance, Humans, Treatment Outcome, Selective Serotonin Reuptake Inhibitors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.